Literature DB >> 7714699

Congenital nasolacrimal duct obstruction: natural history and the timing of optimal intervention.

T O Paul1, R Shepherd.   

Abstract

Nasolacrimal duct obstruction (NLDO) is a relatively common clinical problem. Debate continues about optimal management. Intervening early and intervening late each have advantages and disadvantages. We reviewed the world literature on NLDO. We assembled information on occurrence, natural history, and results of treatment. Spontaneous remission data were used to derive the probability of continued obstruction versus age. The prevalence a hypothesized treatment-resistant form of NLDO was estimated. Symptomatic NLDO probably occurs in 5 to 6% of infants. Given a symptomatic case under the age of 14 months, the probability of spontaneous remission within the following month appears to be approximately one of three. Probe failure risk increases with age, doubling every 6 months. Increasing probe failure risk may be due to self-selection. Preliminary analysis of management strategies suggests that lacrimal duct probing at age 4 months in the office is the most cost-effective strategy. Further descriptive studies of NLDO remission and treatment are indicated.

Entities:  

Mesh:

Year:  1994        PMID: 7714699     DOI: 10.3928/0191-3913-19941101-04

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  32 in total

1.  Value of nasal endoscopy and probing in the diagnosis and management of children with congenital epiphora.

Authors:  C J MacEwen; J D Young; C W Barras; B Ram; P S White
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Paediatric powered endonasal dacryocystorhinostomy.

Authors:  Dania Al-Nuaimi; Clare Inkster; Christopher Lobo
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-26       Impact factor: 2.503

3.  Long-term results of probing guided with soft cannula in children with congenital nasolacrimal duct obstruction.

Authors:  Dilek Yuksel; Pınar Altiaylik Ozer
Journal:  Jpn J Ophthalmol       Date:  2013-11-16       Impact factor: 2.447

4.  The child with epiphora.

Authors:  W N Clarke
Journal:  Paediatr Child Health       Date:  1999-07       Impact factor: 2.253

Review 5.  Probing for congenital nasolacrimal duct obstruction.

Authors:  Carisa Petris; Don Liu
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

6.  Office probing for treatment of nasolacrimal duct obstruction in infants.

Authors:  Aaron M Miller; Danielle L Chandler; Michael X Repka; Darren L Hoover; Katherine A Lee; Michele Melia; Paul J Rychwalski; David I Silbert; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Graham E Quinn; Nick A Sala; Susan Schloff; David K Wallace; Nicole C Foster; Kevin D Frick; Richard P Golden; Scott R Lambert; D Robbins Tien; David R Weakley
Journal:  J AAPOS       Date:  2014-02       Impact factor: 1.220

7.  Pediatric nasolacrimal duct obstruction-benefit of a combined therapeutic approach.

Authors:  Miloš Fischer; Iris-Susanne Horn; Mathias Otto; Mandy Pirlich; Andreas Dietz; Christian Mozet
Journal:  World J Pediatr       Date:  2017-05-24       Impact factor: 2.764

8.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

9.  A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction.

Authors: 
Journal:  Arch Ophthalmol       Date:  2012-12

10.  Paediatric endoscopic endonasal dacryocystorhinostomy in congenital nasolacrimal duct obstruction.

Authors:  Igal Leibovitch; Dinesh Selva; Angelo Tsirbas; Edward Greenrod; John Pater; Peter J Wormald
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.